Author

M. Courtney Safir

Observed names: M Courtney Safir, M. C. Safir

Institution: Institute for Clinical Pharmacodynamics (United States)

Observed institutions: Institute for Clinical Pharmacodynamics (United States), University at Buffalo, State University of New York

ORCID: 0000-0003-0452-682X

Observed ORCID: 0000-0003-0452-682X

OpenAlex ID: A5022312638

Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review

2017 · David M. Jacobs, M. Courtney Safir, et al. · Annals of Clinical Microbiology and Antimicrobials · 47

PDF

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data

2020 · Elizabeth A. Lakota, Scott A. Van Wart, et al. · Antimicrobial Agents and Chemotherapy · 28

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

2020 · M. Courtney Safir, Sujata M. Bhavnani, et al. · Antibiotics · 19

PDF

Population pharmacokinetic analyses for sulbactam–durlobactam using Phase 1, 2, and 3 data

2024 · Anthony P. Cammarata, M. Courtney Safir, et al. · Antimicrobial Agents and Chemotherapy · 12

Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide

2023 · H. Ganesan, V. K. Gupta, et al. · Antimicrobial Agents and Chemotherapy · 9

PDF

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics

2023 · M. Trang, E. A. Lakota, et al. · Antimicrobial Agents and Chemotherapy · 7

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia

2022 · M. Trang, J. P. Hammel, et al. · Antimicrobial Agents and Chemotherapy · 4

Evaluation of an in vivo pulmonary aspergillosis model for triazole susceptibility breakpoint development

2026 · Alex Lepak, Sujata M. Bhavnani, et al. · Antimicrobial Agents and Chemotherapy · 2

Population pharmacokinetic analysis of tobramycin in serum and ELF using data from patients with pneumonia

2025 · Scott A. Van Wart, Michael Trang, et al. · Antimicrobial Agents and Chemotherapy · 2

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies

2022 · Harish Ganesan, M Courtney Safir, et al. · Open Forum Infectious Diseases · 2

PDF

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

2020 · Sujata M. Bhavnani, Jeffrey P. Hammel, et al. · Antimicrobial Agents and Chemotherapy · 2

A Phase 1 First‐in‐Human Single‐Ascending‐Dose Trial With ESB1609, a Selective Agonist to the Sphingosine‐1‐Phosphate Receptor 5

2023 · Nicholas P. France, Christopher Rubino, et al. · Clinical Pharmacology in Drug Development · 1

PDF

619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease

2022 · Sujata M Bhavnani, Sujata M Bhavnani, et al. · Open Forum Infectious Diseases · 1

Impact of obesity on cefazolin pharmacokinetics and optimal dosing for surgical prophylaxis in patients with obesity

2026 · M. Courtney Safir, Michael Trang, et al. · Clinical Infection in Practice

569. Identification of Ampicillin and Vancomycin In Vitro Susceptibility Test Interpretive Criteria for Enterococcus faecalis and Enterococcus faecium

2026 · Sujata M Bhavnani, Jeffrey P Hammel, et al. · Open Forum Infectious Diseases

Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections

2025 · Scott A. Van Wart, M. Courtney Safir, et al. · Antimicrobial Agents and Chemotherapy

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies

2023 · Anthony P Cammarata, Karine Litherland, et al. · Open Forum Infectious Diseases

PDF

Works count: 17

Citation count: 136

H-index: 6

I10-index: 4